Novartis AG (NYSE: NVS) has decided to step back from pursuing the Cytokinetics Inc (NASDAQ: CYTK) acquisition, dealing a blow to the potential deal with the promising heart-drug developer. The biotech company, currently running a sale process, leaves room for speculation on whether Novartis or another suitor might re-emerge or if the company will explore alternative options such as a […]